Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition.
about
PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell linesThe synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus.Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors.The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.PI3K inhibitor enhances the cytotoxic response to etoposide and cisplatin in a newly established neuroendocrine cervical carcinoma cell line.Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase.Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine TumorsNeuroendocrine tumors resistant to mammalian target of rapamycin inhibitors: A difficult conversion from biology to the clinic.hnRNPM guides an alternative splicing program in response to inhibition of the PI3K/AKT/mTOR pathway in Ewing sarcoma cells.Combination treatment of RAD001 and BEZ235 exhibits synergistic antitumor activity via down-regulation of p-4E-BP1/Mcl-1 in small cell lung cancer.Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin.Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.
P2860
Q33618630-11B52494-FB05-44E9-B8D1-53546E8F0B53Q35546455-2EC21CAD-F6ED-46D8-93D7-A662F9735AC6Q36849266-0FDC8C6C-97A8-4717-AF5A-1E870B9805E9Q38331666-45554EB1-89DA-44C4-888D-D9CDDF423CDCQ38695102-38A848F4-2E98-4803-8F42-8A59D39DA1EBQ38704263-F63B4121-948B-4261-AE02-E3BE95F1BC7EQ38786234-6E6E89E6-B2E0-46DA-981B-9E5762705B3CQ38893052-8AE3FB3A-837D-4311-BCED-DEFC48085190Q39156308-AB5F4BE2-612E-45CD-8323-7DCF4E530222Q39735943-450AF85A-AD6C-4FDA-8892-4C8628B97685Q43134817-EE4FC00F-3134-4DA4-8163-30DC375D9FEDQ47116845-D78539BF-06CB-4A05-83D6-61E7B37DE914Q47184289-E3709610-1921-4AAA-B722-7DA04AD2CA3CQ47217432-01EA1849-8B5D-4BDC-80F5-264AF2DABE97Q47393972-F8A74291-9636-466F-826A-94F51BC25581
P2860
Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Combined therapy with RAD001 e ...... cell lines to mTOR inhibition.
@en
type
label
Combined therapy with RAD001 e ...... cell lines to mTOR inhibition.
@en
prefLabel
Combined therapy with RAD001 e ...... cell lines to mTOR inhibition.
@en
P2093
P2860
P356
P1433
P1476
Combined therapy with RAD001 e ...... cell lines to mTOR inhibition.
@en
P2093
Claudio Sette
Fabrizio Loreni
Gianfranco Delle Fave
Ilaria Passacantilli
Sara Calabretta
Sara Caldarola
P2860
P304
P356
10.18632/ONCOTARGET.2111
P407
P577
2014-07-01T00:00:00Z